New approaches and consequences for elderly cancer patients with focus on melanoma

Rob Roel Henry van den Brom

New approaches and consequences for elderly cancer patients with focus on melanoma

Rob Roel Henry van den Brom

Research output: Thesis › Thesis fully internal (DIV)

1428 Downloads (Pure)

Abstract

- We present modified NCCN evidence blocks to classify clinical benefit for elderly metastatic renal cell carcinoma patients.
- The efficacy of newly registered therapies for metastatic melanoma obtained high scores for clinical effect and underscores the relevance to seriously consider these novel treatment approaches in the elderly.
- The CD4+ T cell compartment of young melanoma patients shows strong signs of activation, whereas these signs are lacking in CD4+ T cells of old melanoma patients.
- A Dutch registry demonstrates that treatment with ipilimumab for metastatic melanoma is equally effective in elderly and younger patients, is safe in patients ≥ 65 years and has similar efficacy and toxicity for both genders.
- Early development of hypophosphatemia during imatinib treatment does not predict treatment efficacy.

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Groningen
Supervisors/Advisors	Hospers, Geke, Supervisor de Vries, Liesbeth, Supervisor Schröder, Carolien, Co-supervisor
Award date	25-Sept-2017
Place of Publication	[Groningen]
Publisher	Rijksuniversiteit Groningen
Print ISBNs	978-94-034-0081-5
Electronic ISBNs	978-94-034-0080-8
Publication status	Published - 2017

Access to Document

Title and contentsFinal publisher's version, 237 KB
Chapter 1Final publisher's version, 394 KB
Chapter 2Final publisher's version, 732 KB
Chapter 3Final publisher's version, 806 KB
Chapter 4Final publisher's version, 842 KB
Chapter 5Final publisher's version, 745 KB
Chapter 6Final publisher's version, 704 KB
Chapter 7Final publisher's version, 664 KB
Chapter 8aFinal publisher's version, 358 KB
Publisher version Chapter 8bFinal publisher's version, 61.8 KB
Chapter 8cFinal publisher's version, 514 KB
Chapter 8dFinal publisher's version, 384 KB
Chapter 8eFinal publisher's version, 520 KB
Chapter 9 (Summary)Final publisher's version, 488 KB
Chapter 10 (Summary in Dutch)Final publisher's version, 570 KB
Dankwoord (Acknowledgements)Final publisher's version, 522 KB
PropositionsFinal publisher's version, 84.2 KB

Handle.net

Persistent link

Embargoed Document

Chapter 8b
Final publisher's version, 330 KB
Embargo ends: 01/01/9999

Embargoed Document

Complete thesis
Final publisher's version, 2.83 MB
Embargo ends: 01/01/9999

Cite this

@phdthesis{0e4ecb18a7c24da8978d9ac78f10c52d,

title = "New approaches and consequences for elderly cancer patients with focus on melanoma",

abstract = "- We present modified NCCN evidence blocks to classify clinical benefit for elderly metastatic renal cell carcinoma patients. - The efficacy of newly registered therapies for metastatic melanoma obtained high scores for clinical effect and underscores the relevance to seriously consider these novel treatment approaches in the elderly. - The CD4+ T cell compartment of young melanoma patients shows strong signs of activation, whereas these signs are lacking in CD4+ T cells of old melanoma patients. - A Dutch registry demonstrates that treatment with ipilimumab for metastatic melanoma is equally effective in elderly and younger patients, is safe in patients ≥ 65 years and has similar efficacy and toxicity for both genders. - Early development of hypophosphatemia during imatinib treatment does not predict treatment efficacy.",

author = "\{van den Brom\}, \{Rob Roel Henry\}",

year = "2017",

language = "English",

isbn = "978-94-034-0081-5",

publisher = "Rijksuniversiteit Groningen",

school = "University of Groningen",

}

TY - BOOK

T1 - New approaches and consequences for elderly cancer patients with focus on melanoma

AU - van den Brom, Rob Roel Henry

PY - 2017

Y1 - 2017

N2 - - We present modified NCCN evidence blocks to classify clinical benefit for elderly metastatic renal cell carcinoma patients. - The efficacy of newly registered therapies for metastatic melanoma obtained high scores for clinical effect and underscores the relevance to seriously consider these novel treatment approaches in the elderly. - The CD4+ T cell compartment of young melanoma patients shows strong signs of activation, whereas these signs are lacking in CD4+ T cells of old melanoma patients. - A Dutch registry demonstrates that treatment with ipilimumab for metastatic melanoma is equally effective in elderly and younger patients, is safe in patients ≥ 65 years and has similar efficacy and toxicity for both genders. - Early development of hypophosphatemia during imatinib treatment does not predict treatment efficacy.

AB - - We present modified NCCN evidence blocks to classify clinical benefit for elderly metastatic renal cell carcinoma patients. - The efficacy of newly registered therapies for metastatic melanoma obtained high scores for clinical effect and underscores the relevance to seriously consider these novel treatment approaches in the elderly. - The CD4+ T cell compartment of young melanoma patients shows strong signs of activation, whereas these signs are lacking in CD4+ T cells of old melanoma patients. - A Dutch registry demonstrates that treatment with ipilimumab for metastatic melanoma is equally effective in elderly and younger patients, is safe in patients ≥ 65 years and has similar efficacy and toxicity for both genders. - Early development of hypophosphatemia during imatinib treatment does not predict treatment efficacy.

M3 - Thesis fully internal (DIV)

SN - 978-94-034-0081-5

PB - Rijksuniversiteit Groningen

CY - [Groningen]

ER -

New approaches and consequences for elderly cancer patients with focus on melanoma

Abstract

Access to Document

Handle.net

Embargoed Document

Embargoed Document

Fingerprint

Cite this